丙型肝炎病毒高变区1抗体的交叉反应性分析

目的探索检测丙型肝炎病毒（HCVJ高变区1（HVR1）抗体交叉反应性的意义。方法采用16种重组的HVRI抗原包被，酶联免疫吸附检测不同病程及不同干扰素治疗效果HCV感染者血清中HVR1抗体的情况，分析其高变区抗体交叉反应性。结果在慢性丙型肝炎、肝硬化和肝细胞癌这三组患者血清中HVR1抗体交叉反应阳性数目分别为10．93±4．98、12±5．57和10．64±4．83，三组间差异无统计学意义（P〉0．05）；对干扰素治疗效果好的患者HVR1抗体交叉反应阳性数为13．85±2．85，治疗效果差的患者为7±5．27，前者显著高于后者（P〈0．05）。但两者治疗前HCV病毒载量差异无统计学意义（P〉0...

Full description

Saved in:
Bibliographic Details
Published in临床肝胆病杂志 Vol. 27; no. 8; pp. 818 - 820
Main Author 严艳 修冰水 殷继明 张贺秋 李卓
Format Journal Article
LanguageChinese
Published 北京市肝病研究所,北京,100069%军事医学科学院基础医学研究所,北京,100850 2011
Subjects
丙型
肝炎
肝炎病毒属
肝炎,丙型
肝炎病毒属
Online AccessGet full text
ISSN1001-5256

Cover

More Information
Summary:目的探索检测丙型肝炎病毒（HCVJ高变区1（HVR1）抗体交叉反应性的意义。方法采用16种重组的HVRI抗原包被，酶联免疫吸附检测不同病程及不同干扰素治疗效果HCV感染者血清中HVR1抗体的情况，分析其高变区抗体交叉反应性。结果在慢性丙型肝炎、肝硬化和肝细胞癌这三组患者血清中HVR1抗体交叉反应阳性数目分别为10．93±4．98、12±5．57和10．64±4．83，三组间差异无统计学意义（P〉0．05）；对干扰素治疗效果好的患者HVR1抗体交叉反应阳性数为13．85±2．85，治疗效果差的患者为7±5．27，前者显著高于后者（P〈0．05）。但两者治疗前HCV病毒载量差异无统计学意义（P〉0．05）。结论HVRI抗体的交叉反应性与HCV感染的严重程度无明显关系，但可能成为一项干扰素疗效的辅助预测指标。
Bibliography:Objective To evaluate the significance of cross - reactive antibodies against hypervariable region 1 （ HVR1 ） in hepatitis C virus （HCV） infected patients. Methods The cross - reactivity of HVR1 antibodies in the serum of HCV patients of different disease course and diflhrent response with interferon treatment were semiquantitatively done through counting the positive reaction with 16 representative HVRI proteins coated on the micro - plates by ELISA. Results The cross - reactivity of ItVR1 antibodies in the group of chrnnic hepatitis, cirrhosis and HCC was 10.93±4. 979, 12±5.57, 10.64±4.83 respectively. There was no significant difference in the three groups （ P 〉 0. 05 ）. The cross -reactivity of HVRI antibodies was 13.85 _ 2.85 in patients with sustained virological response （SVR） , which was significantly higher than that in the patients with no response to IFN （7±5.27 ）. There was no difference in the HCV RNA pretreatment level between the effective and ineffective groups （ P 〉 0.05 ）. Conclusion The cro
ISSN:1001-5256